Home/ Stocks/ PTGX

Protagonist Therapeutics, Inc

PTGX XNAS

$145.87 -0.31 (-0.21%) ▼ 15-min delayed

Open

$146.18

High

$147.32

Low

$144.44

Volume

321.1K

Market Cap

$9.46B

About Protagonist Therapeutics, Inc

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 131 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$213.47M	$162.85M	$2.47
Q1 2026	$56.37M	$3.78M	$0.06
FY 2025	$46.02M	$-130,149,000	$-2.05
Q3 2025	$4.71M	$-39,339,000	$-0.62

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for PTGX yet. Check out our latest market news or earnings calendar.

Get PTGX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Protagonist Therapeutics, Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.